Patrick Marcellin
#97,226
Most Influential Person Now
Researcher
Patrick Marcellin's AcademicInfluence.com Rankings
Patrick Marcellinphilosophy Degrees
Philosophy
#3715
World Rank
#5951
Historical Rank
Logic
#1351
World Rank
#2081
Historical Rank

Download Badge
Philosophy
Patrick Marcellin's Degrees
- PhD Biochemistry Université Paris Cité
Why Is Patrick Marcellin Influential?
(Suggest an Edit or Addition)Patrick Marcellin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (2004) (2954)
- Telaprevir for previously untreated chronic hepatitis C virus infection. (2011) (2539)
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus (1998) (2325)
- Boceprevir for previously treated chronic HCV genotype 1 infection. (2011) (1711)
- Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014) (1667)
- Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C (2005) (1426)
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study (2013) (1410)
- Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. (2003) (1367)
- Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. (2005) (1285)
- Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. (2004) (1118)
- Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. (2003) (1015)
- Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) (1998) (929)
- Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. (2006) (879)
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. (2004) (838)
- Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. (2008) (677)
- Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. (2010) (657)
- Hepatitis C: the clinical spectrum of the disease. (1999) (624)
- Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy (1997) (614)
- Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. (2017) (603)
- Treatment of chronic viral hepatitis. (1994) (572)
- Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. (2006) (560)
- Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. (2008) (553)
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy (2006) (543)
- Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases (2006) (514)
- Non‐invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B (2009) (505)
- Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C (1995) (501)
- Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients (2009) (483)
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. (2004) (471)
- Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. (2005) (462)
- Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men (1999) (455)
- Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC (2006) (455)
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. (2013) (449)
- Fibrosis and disease progression in hepatitis C (2002) (446)
- Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B (2009) (430)
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
- Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (2014) (408)
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. (2017) (403)
- EASL International Consensus Conference on Hepatitis C (1999) (383)
- STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (2005) (379)
- Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients (2006) (364)
- The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long‐term retrospective cohort study (2001) (355)
- Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C (1998) (348)
- Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (2019) (343)
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study (2014) (342)
- Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. (2016) (341)
- Recombinant human α‐interferon in patients with chronic non‐A, non‐B hepatitis: A multicenter randomized controlled trial from France (1991) (335)
- Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening (2018) (333)
- Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. (2010) (331)
- Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues (2007) (328)
- Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. (2008) (324)
- Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. (2011) (323)
- Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. (2009) (317)
- Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. (2011) (309)
- Long‐term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B (2008) (306)
- Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study (2013) (295)
- Global burden of disease (GBD) for hepatitis C (2004) (291)
- Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B (2006) (280)
- Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C (2004) (280)
- Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. (2007) (279)
- Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. (2016) (279)
- CMV drives clonal expansion of NKG2C+ NK cells expressing self‐specific KIRs in chronic hepatitis patients (2012) (276)
- Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. (2007) (276)
- Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial (2015) (273)
- Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. (2014) (272)
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis (2015) (256)
- HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B (2008) (247)
- The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
- HCV direct‐acting antiviral agents: the best interferon‐free combinations (2014) (243)
- Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. (2002) (242)
- Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection (2014) (235)
- Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data (2004) (234)
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (2018) (227)
- Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C (2007) (226)
- Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. (2008) (225)
- Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil (2003) (224)
- Efficacy of peginterferon alpha‐2b in chronic hepatitis delta: Relevance of quantitative RT‐PCR for follow‐up (2006) (218)
- Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. (2002) (218)
- Pathogenesis, diagnosis and management of hepatitis C. (2000) (216)
- Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment (1999) (214)
- Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. (2007) (213)
- Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
- No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B (2014) (209)
- Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives (2016) (205)
- The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report (2010) (202)
- Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C (2011) (199)
- Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
- Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. (2014) (196)
- Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C (2012) (194)
- IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. (2012) (192)
- Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin (2010) (183)
- High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. (2009) (183)
- No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus (2011) (179)
- Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin (2010) (179)
- Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-2b (2009) (176)
- Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. (2008) (175)
- Therapy of hepatitis C: Patients with normal aminotransferase levels (1997) (173)
- Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA (2001) (173)
- The intraportal lymphoid nodule and its environment in chronic active hepatitis C: An immunohistochemical study (1993) (173)
- Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. (2018) (170)
- Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. (2005) (169)
- Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. (2005) (167)
- Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis (2010) (163)
- New direct‐acting antivirals' combination for the treatment of chronic hepatitis C (2011) (161)
- Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study (2005) (159)
- Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B (2015) (159)
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). (2015) (157)
- Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. (2015) (157)
- Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. (1993) (155)
- Long-term outcome of hepatitis C infection after bone marrow transplantation. (2004) (154)
- Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. (2011) (154)
- Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose (2002) (153)
- Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment (1999) (153)
- Hepatitis B and hepatitis C in 2009 (2009) (150)
- A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B (2004) (148)
- Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. (2010) (147)
- Natural history of hepatitis B. (2005) (147)
- Autoimmune chronic hepatitis exacerbated by alpha-interferon. (1992) (146)
- Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C (1993) (143)
- Diabetes mellitus is an independent prognostic factor for major liver‐related outcomes in patients with cirrhosis and chronic hepatitis C (2014) (141)
- Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C (2012) (141)
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. (2014) (141)
- Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy (1999) (140)
- Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials (2015) (135)
- Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients (2012) (133)
- Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow (2012) (133)
- Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. (2000) (132)
- Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. (2010) (130)
- Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study (2007) (128)
- Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression (2015) (126)
- Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection (2007) (126)
- Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C (2003) (126)
- Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. (2006) (125)
- The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C (2012) (125)
- Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study (2002) (122)
- Gene expression and hepatitis C virus infection (2008) (122)
- Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy (2006) (121)
- 1369 TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL (2011) (120)
- Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. (2008) (120)
- 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL (2013) (119)
- Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. (1999) (119)
- In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C (2010) (118)
- Treatment of hepatitis C virus infection with direct‐acting antiviral agents: 100% cure? (2018) (118)
- Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. (1998) (113)
- Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients (2013) (113)
- A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care (2013) (109)
- Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti‐HBe or HBsAg to Anti‐HBs seroconversion in patients with chronic hepatitis B (1992) (109)
- Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. (2001) (109)
- Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. (1995) (106)
- Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load (2013) (106)
- Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. (1997) (105)
- HBsAg quantification: useful for monitoring natural history and treatment outcome (2014) (104)
- High sustained virologic response rates in rapid virologic response patients in the large real‐world PROPHESYS cohort confirm results from randomized clinical trials (2012) (104)
- Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. (1995) (103)
- A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. (2000) (102)
- Genomics and HCV infection: progression of fibrosis and treatment response. (2012) (101)
- Redevelopment of hepatitis B surface antigen after renal transplantation. (1991) (101)
- Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. (2017) (100)
- Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. (2013) (98)
- Recombinant Interferon-α for Chronic Hepatitis C in Patients Positive for Antibody to Human Immunodeficiency Virus (1992) (97)
- Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection (2007) (95)
- Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort) (2015) (95)
- Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. (2014) (94)
- No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment (2017) (92)
- Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. (2015) (90)
- Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. (2013) (89)
- Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B–related end‐stage liver disease (1994) (88)
- Treatment of hepatitis C. The 2002 French consensus (2003) (88)
- Global Burden of Disease (GBD) for Hepatitis C The Global Burden of Hepatitis C Working Group (2004) (88)
- Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real‐life, observational study (2011) (88)
- TWO YEAR TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT AND ADEFOVIR DIPIVOXIL (ADV) SWITCH DATA IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102), PRELIMINARY ANALYSIS (2008) (88)
- Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. (2019) (87)
- Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C (2006) (86)
- Hepatitis after intravenous buprenorphine misuse in heroin addicts. (2001) (86)
- Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naïve patients infected with HCV genotype 1 (2012) (86)
- Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. (1998) (84)
- Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
- Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin (2008) (81)
- Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). (2016) (80)
- Protease and polymerase inhibitors for the treatment of hepatitis C (2009) (79)
- Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open- (2017) (79)
- Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 (2009) (78)
- Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. (2014) (78)
- Long‐term clearance of hepatitis C virus following interferon α‐2b or peginterferon α‐2b, alone or in combination with ribavirin (2013) (77)
- Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. (2003) (77)
- Interferon free therapy with direct acting antivirals for HCV (2013) (76)
- Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. (2013) (76)
- Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir) (2016) (76)
- A randomized, placebo‐controlled study to evaluate the efficacy of 12‐month famciclovir treatment in patients with chronic hepatitis B e antigen–positive hepatitis B (2000) (76)
- Efficacy and Safety of Two-Dose Regimens of Peginterferon Alpha-2a Compared with Interferon Alpha-2a in Chronic Hepatitis C: A Multicenter, Randomized Controlled Trial (2004) (76)
- Cytokine--chemokine and apoptotic signatures in patients with hepatitis C. (2007) (75)
- Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a (2009) (73)
- Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. (2001) (72)
- Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C (2010) (72)
- Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis (2002) (72)
- Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. (2007) (71)
- Shaving as potential source of hepatitis C virus infection (1995) (70)
- Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection (2019) (69)
- Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial (2011) (69)
- Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. (2018) (69)
- Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. (1990) (68)
- Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B (1990) (68)
- P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy (2006) (68)
- Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a (2008) (67)
- Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. (2011) (67)
- Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. (1994) (66)
- Influence of Hepatitis G Virus Infection on the Severity of Liver Disease and Response to Interferon- in Patients with Chronic Hepatitis C (1997) (66)
- Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. (1994) (66)
- The role of HBsAg quantification for monitoring natural history and treatment outcome (2013) (64)
- Second‐wave IFN‐based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir (2014) (64)
- Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. (1994) (62)
- Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa‐2a (1999) (62)
- Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France (2016) (62)
- Changes in autophagic response in patients with chronic hepatitis C virus infection. (2011) (62)
- Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. (1992) (60)
- HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients (2015) (59)
- The negative impact of HBV/HCV coinfection on cirrhosis and its consequences (2017) (59)
- A new step toward standardization of serum hepatitis C Virus–RNA quantification in patients with chronic hepatitis C (2000) (58)
- Second generation (RIBA) test in diagnosis of chronic hepatitis C (1991) (57)
- Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years (2015) (57)
- Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C: A randomized phase II study (2012) (57)
- High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. (2007) (57)
- 1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS (2012) (56)
- Fibrosis and disease progression in hepatitis C (2002) (55)
- Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. (1993) (55)
- Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity (2006) (54)
- Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin (2012) (54)
- 104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS (2008) (53)
- Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort) (2015) (53)
- Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. (2015) (53)
- Mesalazine (5-aminosalicylic acid) induced chronic hepatitis (1999) (52)
- Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. (2011) (51)
- Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. (2015) (51)
- Ectopic hepatocellular carcinoma arising in the left chest wall: a long-term follow-up. (2001) (51)
- Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest–ActiTest) in patients infected by hepatitis B virus (2009) (50)
- Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B (2016) (50)
- Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes (2010) (50)
- Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α‐2a plus ribavirin (2007) (49)
- Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. (2016) (49)
- Treatment of chronic hepatitis B (2005) (48)
- Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? (2007) (48)
- Markers of Inflammation and Fibrosis in Alcoholic Hepatitis and Viral Hepatitis C (2011) (48)
- Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients (2016) (48)
- SERUM TUMOUR NECROSIS FACTOR-α AND TRANSFORMING GROWTH FACTOR-β LEVELS IN CHRONIC HEPATITIS C PATIENTS ARE IMMUNOMODULATED BY THERAPY (2002) (47)
- Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients (2018) (47)
- Treatment of Hepatitis C Virus Genotype 4–Related Cirrhosis: Ribavirin and Interferon Combination Compared With Interferon Alone (2002) (47)
- Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody (2009) (47)
- Clinical relevance of total HCV Core antigen testing for hepatitis C monitoring and for predicting patients’ response to therapy (2003) (47)
- Sarcoidosis during combined interferon alfa and ribavirin therapy in 2 patients with chronic hepatitis C. (2002) (46)
- New and emerging treatment of chronic hepatitis B. (2007) (46)
- Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. (1996) (46)
- Influence of cirrhosis on lamotrigine pharmacokinetics. (2001) (45)
- Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. (2000) (45)
- Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients (2005) (45)
- [8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE? (2007) (45)
- Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. (2014) (45)
- Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy (2004) (44)
- Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. (1992) (44)
- Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa‐2a for HBeAg‐negative patients (2011) (44)
- 1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL (2012) (44)
- Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. (2008) (44)
- Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. (2010) (43)
- Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement (2018) (43)
- Long‐term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal (2013) (43)
- 11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS (2012) (41)
- The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. (2014) (41)
- Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study (2006) (41)
- Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study (2010) (41)
- Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. (2012) (41)
- 69 NEPTUNE STUDY: ON-TREATMENT HBSAG LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBEAG-POSITIVE PATIENTS (2011) (40)
- 103 VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A (40KD) WITH OR WITHOUT LAMIVUDINE: RESULTS OF 4-YEAR FOLLOW-UP (2008) (40)
- Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy (2003) (40)
- 46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES) (2004) (39)
- Integrin up‐regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C (2001) (39)
- Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B (2011) (39)
- 43 LONG TERM TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY AND THE RISK OF HEPATOCELLULAR CARCINOMA (2013) (38)
- Response to antiviral treatment in patients infected with hepatitis B virus genotypes E–H (2009) (38)
- Low frequency of precore hepatitis B virus mutants in anti‐hepatitis B e—positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B (1995) (38)
- MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C (2016) (38)
- Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. (2000) (38)
- LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather* (2015) (38)
- Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis C (2000) (38)
- Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. (2005) (37)
- Recombinant human γ‐interferon in patients with chronic active hepatitis B: Pharmacokinetics, tolerance and biological effects (1990) (37)
- Reactivity to c33c antigen as a marker of hepatitis C virus multiplication. (1992) (36)
- No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection (2018) (36)
- Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis (2005) (35)
- Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis (2018) (35)
- Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
- Chronic hepatitis C: Interferon retreatment of relapsers. A meta‐analysis of individual patient data (1999) (34)
- Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B (2019) (34)
- Improving performance of liver biopsy in fibrosis assessment. (2014) (34)
- Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B (2016) (34)
- Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen–positive patients (2011) (34)
- Randomized controlled trial of adenine arabinoside 5′‐monophosphate in chronic active hepatitis B: Comparison of the efficacy in heterosexual and homosexual patients (1989) (34)
- 917 ON-TREATMENT MONITORING OF HBsAg LEVELS TO PREDICT RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B (2009) (33)
- 57 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 102) (2008) (33)
- Allogeneic hematopoietic cell transplant in HCV-infected patients. (2008) (33)
- 1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS (2013) (32)
- Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve european patients in the quest-1 and quest-2 phase III trials (2014) (32)
- Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. (2006) (32)
- 924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP (2009) (32)
- 725 QUANTITATIVE HBSAG: A NEW SPECIFIC MARKER FOR THE DIAGNOSIS OF HBSAG INACTIVE CARRIAGE (2010) (32)
- Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C. Relationship with severity of disease, viral genotype and response to treatment. (2001) (32)
- Re‐treatment with interferon alfa of patients with chronic hepatitis C (1998) (32)
- P1319 ONCE-DAILY SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE OR TREATMENT-EXPERIENCED CHRONIC HCV GENOTYPE 4-INFECTED PATIENTS: FINAL RESULTS OF A PHASE III TRIAL (2014) (32)
- Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors. (1994) (32)
- Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic Hepatitis B: Week 72 TDF data and week 24 Adefovir dipivoxil switch data (Study 102) (2008) (31)
- Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. (1999) (31)
- Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. (1999) (31)
- O58 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION (2014) (31)
- Auxiliary liver transplantation for fulminant hepatitis B: Results from a series of six patients with special emphasis on regeneration and recurrence of hepatitis B (2002) (31)
- 13 TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B – VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN) (2010) (30)
- LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepather (2015) (30)
- Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C (2005) (30)
- Chronic non-B, non-C hepatitis among blood donors assessed with HCV third generation tests and polymerase chain reaction. (1993) (30)
- Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication (2018) (30)
- Future treatments for hepatitis delta virus infection (2020) (30)
- Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels (2002) (29)
- Transient elastography in chronic viral hepatitis: a critical appraisal (2011) (29)
- 50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B (2006) (29)
- Reduction of MicroRNA 122 Expression in IFNL3 CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C (2014) (29)
- Pegylated Interferon-α2A plus Ribavirin for Chronic Hepatitis C in a Real-Life Setting: The Hepatys French Cohort (2003–2007) (2012) (29)
- Advances in therapy for chronic hepatitis B. (2002) (29)
- Optimal IFN‐free therapy in treatment‐naïve patients with HCV genotype 1 infection (2015) (29)
- Incidence of dysthyroidism during interferon therapy in chronic hepatitis C. (1997) (29)
- Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin (2005) (29)
- Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. (2008) (28)
- HIV coinfection does not compromise liver histological response to interferon therapy in patients with chronic hepatitis C (2002) (28)
- Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing. (2008) (27)
- Serum tumour necrosis factor-alpha and transforming growth factor-beta levels in chronic hepatitis C patients are immunomodulated by therapy. (2002) (27)
- Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B (2007) (27)
- Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study (2015) (27)
- alpha-Interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. (1995) (27)
- Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. (2013) (27)
- Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B (2014) (27)
- Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. (2000) (27)
- Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. (1993) (27)
- IFNL3 (IL28B) polymorphism does not predict long‐term response to interferon therapy in HBeAg‐positive chronic hepatitis B patients (2014) (26)
- Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C. (2006) (26)
- Tolerability of Treatments for Viral Hepatitis (2001) (26)
- Virological analysis of patients receiving Telaprevir administered Q8H or Q12H with Peginterferon-Alfa-2A or -Alfa-2B and Ribavirin in treatment-naive patients with Genotype I hepatitis C: study C208 (2009) (26)
- 76 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN SUBJECTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (ADV) (2008) (26)
- ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B (2018) (26)
- Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. (2007) (26)
- 740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS (2011) (25)
- Hepatitis C virus genotypes in French blood donors (1995) (25)
- Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. (2019) (25)
- Evidence of Hepatitis C Virus Viremia without Detectable Antibody to Hepatitis C Virus in a Blood Donor (2000) (25)
- Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies (2007) (25)
- Prolonged interferon‐alpha therapy of hepatitis B virus‐related decompensated cirrhosis (1997) (24)
- Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C. (2009) (24)
- An update in the management of chronic hepatitis B. (2013) (24)
- The current status of antiviral therapy of chronic hepatitis B. (2005) (24)
- Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux. (1992) (24)
- Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti‐viral activity of clevudine for 12 weeks in patients with chronic hepatitis B (2008) (24)
- Interferon therapy for chronic hepatitis B. (2007) (24)
- Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin. (1997) (23)
- Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial. (2001) (23)
- THREE YEARS OF TENOFOVIR DISOPROXIL (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG plus ) WITH CHRONIC HEPATITIS B (STUDY 103), PRELIMINARY ANALYSIS (2009) (23)
- Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection (1992) (23)
- Anti—pre‐S responses and viral clearance in chronic hepatitis B virus infection (1992) (23)
- Significant gene expression differences in histologically “Normal” liver biopsies: Implications for control tissue (2008) (23)
- [10] THE SAFETY AND EFFICACY OF TARIBAVIRIN PLUS PEGYLATED INTERFERON ALFA-2a VERSUS RIBAVIRIN PLUS PEGYLATED INTERFERON ALFA-2a IN THERAPY-NAIVE PATIENTS INFECTED WITH HCV: PHASE 3 RESULTS (2007) (23)
- ROLE OF REPLICATIVE SENESCENCE IN THE PROGRESSION OF FIBROSIS IN HEPATITIS C VIRUS (HCV) RECURRENCE AFTER LIVER TRANSPLANTATION (2004) (23)
- [53] VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBeAg-NEGATIVE CHB TREATED WITH PEGINTERFERON a-2a (40 kD) ± LAMIVUDINE: 3-YEAR FOLLOW-UP RESULTS (2007) (23)
- A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. (2014) (22)
- 424 Durability of HBEAG seroconversion after adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2004) (22)
- Chronic hepatitis B: back to the future with HBsAg (2009) (22)
- GEMHEP multicenter quality control study of PCR detection of GB virus C/hepatitis G virus RNA in serum (1997) (22)
- Metabolic disorders associated with chronic hepatitis C: impact of genotype and ethnicity (2010) (22)
- Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. (2012) (22)
- Treatment of hepatitis C patients with normal aminotransferases levels. (1999) (21)
- Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France (1996) (21)
- Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. (2011) (21)
- Precore/Core promoter variants to predict significant fibrosis in both HBeAg positive and negative chronic hepatitis B (2015) (21)
- Retreatment with interferon-α of chronic hepatitis C virus infection (1994) (21)
- 85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) (2009) (21)
- O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS (2014) (21)
- Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life (2021) (21)
- 1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN (2010) (20)
- Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials (2015) (20)
- A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 results (2006) (20)
- Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. (2015) (20)
- Long-term efficacy and safety of adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B (CHB) patients (2006) (20)
- Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. (2015) (20)
- Reinforced interferon alpha‐2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial (2003) (20)
- Racial differences in responses to interferon‐β‐1a in chronic hepatitis C unresponsive to interferon‐α: a better response in Chinese patients (2004) (20)
- Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure (2016) (19)
- Etiology of chronic hepatitis in France: predominant role of hepatitis C virus. (1994) (19)
- Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin (2012) (19)
- GS-98-438 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results (2002) (19)
- Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-alpha2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. (2006) (19)
- The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment (2004) (19)
- Type II IgM monoclonal cryoglobulinemia and hepatitis C virus infection. (1991) (19)
- Co-infection VIH-VHC à l'hôpital. Enquête nationale juin 2001 (2003) (19)
- GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results. (2001) (19)
- Haemobilia causing acute pancreatitis after percutaneous liver biopsy: diagnosis by magnetic resonance cholangiopancreatography. (2001) (18)
- Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. (1991) (18)
- HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. (2013) (18)
- A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. (2000) (18)
- Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B (2003) (18)
- Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis? (1990) (18)
- Pegylated Interferon-α2b plus Ribavirin Therapy in Patients with Hepatitis C and Psychiatric Disorders: Results of a Cohort Study (2010) (18)
- Prevalence of hepatitis C virus infection in asymptomatic anti-HIV1 negative pregnant women and their children (1993) (18)
- Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. (2013) (18)
- 45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients (2004) (18)
- Long‐term outcome of primary non‐responders to tenofovir therapy in HIV/HBV‐co‐infected patients: impact of HBV genotype G (2012) (18)
- A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96 (2017) (18)
- Results From the Phase 2 PEARL-I Study: Interferon-Free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection: 438 (2014) (17)
- Assessment of Viral Loads in Patients with Chronic Hepatitis C with AMPLICOR HCV MONITOR Version 1.0, COBAS HCV MONITOR Version 2.0, and QUANTIPLEX HCV RNA Version 2.0 Assays (2000) (17)
- Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α‐2a (40KD) plus ribavirin (2007) (17)
- 903 TENOFOVIR DISOPROXIL FUMARATE (TDF) VERSUS EMTRICITABINE PLUS TDF (FTC/TDF) FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN PATIENTS WITH PERSISTENT VIRAL REPLICATION RECEIVING ADEFOVIR DIPIVOXIL (2009) (17)
- Autoimmune disorders associated with hepatitis C. (1995) (17)
- Quasispecies Analysis and In Vitro Susceptibility of HBV Strains Isolated from HIV–HBV-Coinfected Patients with Delayed Response to Tenofovir (2012) (17)
- [Natural history of dysthyroidism during interferon treatment of chronic hepatitis C]. (1996) (16)
- Acute hepatitis induced by α-interferon, associated with viral clearance, in chronic hepatitis C (1997) (16)
- Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B. (2013) (16)
- Dynamic Evolution of Therapy for Chronic Hepatitis C: How will Novel Agents be Incorporated into the Standard of Care? (2008) (16)
- Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. (2020) (16)
- Acute hepatitis E with severe jaundice: report of three cases. (2007) (16)
- Natural history of hepatitis C and the impact of anti-viral therapy. (2000) (16)
- Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy (2017) (16)
- 52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis (2006) (16)
- Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants. (2008) (16)
- Distribution of hepatitis B virus DNA sequences in different peripheral blood mononuclear cell subsets in HBs antigen‐positive and negative patients (1994) (16)
- 1058 ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 1 HEPATITIS C INFECTION WHO FAILED PREVIOUS IFN-BASED THERAPY (2009) (16)
- 1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS (2012) (16)
- 425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS (2011) (16)
- The need for histological subclassification of cirrhosis: a systematic review and meta‐analysis (2016) (15)
- HBsAg Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2A in Chronic Hepatitis B: Long-Term Results of a Global Randomized Controlled Trial (2016) (15)
- Absence of effect of zidovudine on replication of hepatitis B virus in patients with chronic HIV and HBV infection. (1989) (15)
- A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results (2016) (15)
- Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine (2007) (15)
- Genotype 1 is associated with a slower progression of fibrosis in untreqted patients with mild chronic hepatitis C (2001) (15)
- Predictive value of alt levels on histological findings in chronic hepatitis C: a European collaborative study (2001) (14)
- Exacerbation of multiple sclerosis after the administration of recombinant human interferon alfa. (1989) (14)
- Acute pulmonary embolism: a rare complication of a large non-parasitic hepatic cyst (2004) (14)
- 95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine (2004) (14)
- 865 12 WEEK RESPONSE-GUIDED TREATMENT WITH THE NS5A INHIBITOR, GS-5885, THE NS3 PROTEASE INHIBITOR, GS-9451, PLUS PEGYLATED INTERFERON/RIBAVIRIN IN TREATMENT NAÏVE GENOTYPE 1 HEPATITIS C INFECTED PATIENTS (2013) (14)
- Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon (1991) (14)
- Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapy. (2002) (14)
- Detection of serum HBV-DNA by polymerase chain reaction (PCR) in patients before reactivation of chronic hepatitis B. (1992) (14)
- 503 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2006) (14)
- Non‐virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort (2019) (14)
- Baseline alt predicts histologic and serologic response in patients with HBeAg+ chronic hepatitis B treated with adefovir dipivoxil (ADV) (2002) (14)
- 66 HIGH SUSTAINED VIRAL RESPONSE AT 12- AND 24-WEEK FOLLOW-UP OF MK-5172 WITH PEGYLATED INTERFERON alfa-2b AND RIBAVIRIN (PR) IN HCV GENOTYPE 1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS (2013) (14)
- New therapies for hepatitis delta virus infection (2021) (14)
- Accurate model predicting sustained response at week 4 of therapy with pegylated interferon with ribavirin in patients with chronic hepatitis C (2006) (14)
- Hepatocellular carcinoma with normal adjacent liver. Hepatitis B virus DNA status. (1989) (14)
- HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment (2010) (14)
- Adenine arabinoside 5'-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication. (1995) (13)
- Insulin resistance: a major factor associated with significant liver fibrosis in Egyptian patients with genotype 4 chronic hepatitis C (2013) (13)
- [613] VIROLOGICAL RESPONSE AT 4 AND 12 WEEKS PREDICT HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN (2007) (13)
- [Management of hepatitis B and C]. (2005) (13)
- Chronic viral hepatitis (2003) (13)
- Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure (2009) (13)
- Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort (2017) (13)
- Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B (2005) (13)
- 492 A phase II, placebo-controlled study of merimepodib (XV-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin (2004) (13)
- Prevalence of Hepatitis C Virus Infection in Patients Hospitalized for Hepatitis A (1999) (13)
- Lessons from a multicentre study of the detectability of viral genomes based on a two-round quality control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction assay. (2000) (13)
- Detection of an HCV chronic carrier state without anti-HCV antibody in a blood donor during 28 monthsDécouverte d'une infection chronique par le VHC sans séroconversion chez un donneur de sang en France pendant 28 mois (2000) (12)
- A Personalized Approach to Optimize Hepatitis B Treatment in Treatment-naive Patients (2010) (12)
- 56 ON-TREATMENT RESPONSE-GUIDED THERAPY WITH TELAPREVIR Q8H OR Q12H COMBINED WITH PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HEPATITIS C (STUDY C208) (2010) (12)
- O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial (2015) (12)
- Neutralizing antibodies to interferon‐α and circulating interferon in patients with chronic hepatitis C non‐responding to pegylated interferon plus ribavirin re‐treated by pegylated interferon‐α‐2a and ribavirin (ANRS HC16 GAMMATRI substudy*) (2010) (11)
- SCG10 expression on activation of hepatic stellate cells promotes cell motility through interference with microtubules. (2010) (11)
- Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection (2021) (11)
- [Hepatitis C virus, interferon alpha, and dysthyroidism]. (1993) (11)
- Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability (2010) (11)
- O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB) (2015) (11)
- Corrigendum to “Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3” [J Hepatol 40 (2004) 939–999] (2005) (11)
- 162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial (2008) (11)
- Interferon‐α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection (2005) (10)
- A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3 (2016) (10)
- Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. (2003) (10)
- Interferon-alpha therapy for chronic hepatitis C in special patient populations. (1996) (10)
- 869a Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial (2013) (10)
- 804 SUSTAINED VIROLOGIC RESPONSE AFTER PEGINTERFERON ALFA-2B AND RIBAVIRIN TREATMENT PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW-UP (2008) (10)
- Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (2006) (10)
- Response-Guided Therapy: Optimizing Treatment now and in the Future (2008) (10)
- Indeterminate third-generation recombinant immunoblot assay in hepatitis C virus infection. Group d'Etudes Moléculaires des Hépatites (GEMHEP). (1994) (10)
- Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients (2019) (10)
- Viral hepatitis: Impressive advances but still a long way to eradication of the disease (2014) (9)
- 743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment (2006) (9)
- [Discovery of a chronic HVC infection without seroconversion in a blood donor in France during 28 months]. (2000) (9)
- Accumulation of Intrahepatic TNF-α-Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection (2016) (9)
- Impact of Treatment against Hepatitis C Virus on Overall Survival of Naive Patients with Advanced Liver Disease (2014) (9)
- Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon (2010) (9)
- CD4+/CD8+ ratio of liver‐derived lymphocytes is related to viraemia and not to hepatitis C virus genotypes in chronic hepatitis C (1995) (9)
- Effect of newer oral antiviral agents on future therapy of chronic hepatitis B (2010) (9)
- Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin: Analyses of Pre-Defined Subpopulations in the Phase 3 Advance Trial (2011) (9)
- IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C (2015) (9)
- 1218 HIGH SUSTAINED VIROLOGICAL RESPONSE (SVR) RATE AFTER DANOPREVIR FOR ONLY 14 DAYS ASSOCIATED WITH PEG-INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE CHRONIC HCV GENOTYPE 1 PATIENTS (2011) (9)
- CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a (2009) (9)
- [Pegylated interferon: new progress in treatment for chronic hepatitis C]. (2000) (9)
- Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C (2004) (9)
- [Steatosis during chronic hepatitis C: the role of insulin resistance and viral factors]. (2007) (9)
- Solitary pulmonary metastasis arising thirteen years after liver transplantation for HBV-related hepatocellular carcinoma. (2006) (9)
- P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER (2015) (9)
- 49 Association between HBeAg seroconversion and sustained HBV-DNA suppression in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) for HBeAg-positive chronic hepatitis B (CHB) (2006) (9)
- 805 HCV-RNA STATUS AT WEEK 12 OF TREATMENT WITH PEGINTERFERON ALFA-2A/RBV PREDICTS SVR IN PATIENTS WITH PRIOR NON-RESPONSE TO PEGYLATED INTERFERON ALFA-2B/RBV: RESULTS FROM REPEAT STUDY (2008) (8)
- Severity of liver disease among chronic hepatitis C patients: An observational study of 4594 patients in five European countries (2015) (8)
- Clevudine: a promising therapy for the treatment of chronic hepatitis B (2008) (8)
- Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy. (2008) (8)
- Predictors associated with treatment initiation and switch in a real‐world chronic hepatitis B population from five European countries (2014) (8)
- Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase (2020) (8)
- [HBsAg seroclearance: prognostic value for the response to treatment and the long-term outcome]. (2010) (8)
- BILN 2061: a major step toward new therapeutic strategies in hepatitis C (2004) (8)
- 739 EFFECTS OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN CHRONIC HBV PATIENTS IN THREE GLOBAL RANDOMIZED STUDIES (2011) (8)
- Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis (2021) (8)
- 532 SIGNIFICANT GENOTYPE-SPECIFIC ASSOCIATION OF HEPATITIS B SURFACE ANTIGEN LEVEL AND SEVERITY OF LIVER DISEASE IN PATIENTS WITH CHRONIC HEPATITIS B (2012) (8)
- Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice. (2011) (8)
- Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients (2014) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- 923 SAFETY AND EFFICACY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE THERAPY IN LAMIVUDINE EXPERIENCED PATIENTS (2009) (8)
- [Alpha interferon-induced eczema in atopic patients infected by hepatitis C virus: 4 case reports]. (2000) (8)
- Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B (2022) (8)
- Virological and serological tools to optimize the management of patients with chronic hepatitis B (2016) (8)
- S1001 Clearance of HCV At 5 Year Follow-Up for Peginterferon Alfa-2b ± Ribavirin Is Predicted By Sustained Virologic Response At 24 Weeks Post Treatment (2008) (8)
- Comparison of the sensitivity of nested PCR in the 5' non-coding and the NS5 regions of the HCV genome. (1994) (8)
- P1324 LEDIPASVIR (LDV) AND SOFOSBUVIR (SOF) COMBINATION IMPROVES PATIENT-REPORTED OUTCOMES (PRO) DURING TREATMENT OF CHRONIC HEPATITIS C (CH-C) PATIENTS: RESULTS FROM THE ION-1 CLINICAL TRIAL (2014) (8)
- Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. (1990) (8)
- Chronic Hepatitis B Treatment Initiation and Modification Patterns in Five European Countries: A 2-Year Longitudinal, Non-Interventional Study (2014) (7)
- How to be a great reviewer: an editor's view (2008) (7)
- 11 Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon alpha-2b (12kd)/ribavirin non-responders: Interim analysis of the repeat study (2006) (7)
- Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment. (1994) (7)
- 531 TENOFOVIR DF TREATMENT IS SAFE AND WELL TOLERATED IN CHRONIC HEPATITIS B (CHB) PATIENTS WITH BASELINE DECREASED GLOMERULAR FILTRATION RATE (2012) (7)
- [124] 76 WEEK FOLLOW UP OF HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TELBIVUDINE, ADEFOVIR OR SWITCHED FROM ADEFOVIR TO TELBIVUDINE (2007) (7)
- HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort (2017) (7)
- Clinical trial: interferon alpha‐2b continuous long‐term therapy vs. repeated 24‐week cycles for re‐treating chronic hepatitis C (2007) (7)
- Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. (1997) (7)
- What is the safe duration of therapy for patients infected with HCV genotype 6? (2009) (7)
- All-oral Dual Therapy with Daclatasvir and Asunaprevir in Patients with HCV Genotype 1B Infection (2014) (7)
- Clevudine: a promising therapy for the treatment of chronic hepatitis B. (2008) (7)
- À La Carte Interferon for Hepatitis C? (2000) (7)
- Impact of age on viral kinetics of peginterferon alfa‐2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort (2014) (6)
- New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort) (2016) (6)
- 689 LACK OF INFLUENCE OF BASELINE GENOTYPE ON ANTIVIRAL RESPONSE IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION RECEIVING TENOFOVIR DF 300 MG QD FOR 1 YEAR (2008) (6)
- [Infection of ascitic fluid by perforation of a sclerodermic colon]. (1992) (6)
- High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients (2010) (6)
- 21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS (2009) (6)
- Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. (2017) (6)
- Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy. (2012) (6)
- [Treatment of viral hepatitis C]. (1994) (6)
- 502 Efficacy and safety of peginterferon alpha-2a (40KD) (PEGASYS) in patients with chronic hepatitis B who had received prior treatment with nucleos(T)IDE analogues - the pegalam cohort (2006) (6)
- Steatosis in hepatitis C: What does it mean? (2003) (6)
- Tenofovir Disoproxil Fumarate (TDF) Shows Similar Virologic Suppression and Safety Between Asians and Non-Asians With Chronic Hepatitis B (CHB) (2011) (6)
- 683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY (2008) (6)
- Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study (2015) (6)
- 1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B (2003) (6)
- Combination therapy for chronic hepatitis C. (1999) (6)
- S1937 Type of Response to Prior Pegylated Interferon Alfa-2b (12KD)/RBV Predicts Subsequent Response to Retreatment with Peginterferon Alfa-2a (40KD)/RBV (2008) (6)
- P1061 LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY (2014) (6)
- Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml) (2015) (6)
- M1923 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF for Treatment of Chronic Hepatitis B (CHB) in Subjects with Persistent Viral Replication Receiving Adefovir Dipivoxil (ADV) (2008) (6)
- Virological and histological characteristics in anti-HCV positive subjects with normal transaminases levels (1995) (6)
- M1913 Lack of Influence of Baseline Genotype On Antiviral Response in Subjects with Chronic Hepatitis B Infection Receiving Tenofovir Df 300 Mg Qd for 1 Year (2008) (6)
- 778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS (2010) (6)
- Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy (2003) (5)
- 241 Long-term (96 weeks) adefovir dipivoxil in HBEAG negative chronic hepatitis results in significant virological, biochemical and histological improvement (2003) (5)
- TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL (2011) (5)
- 836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim Results (2012) (5)
- Phase 2 study of Telaprevir administered Q8 or Q12H with Peginterferon-Alfa-2A or Alfa-2B and ribavirin in treatment-naive subjects with genotype 1 hepatitis C: week 4 interim results (2008) (5)
- [3 cases of polyarthritis treated with recombinant alfa interferon]. (1992) (5)
- [Managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B]. (2006) (5)
- Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies (2012) (5)
- Quantitative measurement of hepatitis C virus core antigen is affected by the presence of cryoglobulins (2006) (5)
- W1806 Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis (2009) (5)
- O115 PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE (2014) (5)
- [HCV non-responder patients: definition of non-response and treatment strategy]. (2007) (5)
- Lack of polymerase chain reaction amplification in the 5' region of a hepatitis C virus isolate. (1992) (5)
- 468 Evidence for high rates of HCV and HBV related mortality in FRANCE: A large-scale national survey (2006) (5)
- Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study (2016) (5)
- P0600 : Predictive factors of cirrhosis, hepatic decompensation and hepatocellular carcinoma in patients with chronic hepatitis delta (2015) (5)
- Viral hepatitis: towards the eradication of HCV and a cure for HBV (2015) (5)
- Treatment of chronic hepatitis C with alpha-interferon. (1992) (5)
- IDDF2018-ABS-0107 Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF) (2018) (5)
- [792] IMPACT OF ADEFOVIR DIPIVOXIL ON LIVER FIBROSIS AND ACTIVITY ASSESSED WITH FIBROTEST-ACTITEST IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION (2007) (5)
- Anti‐thyroid autoantibodies and hepatitis C virus (1994) (5)
- HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients (2018) (5)
- [Treatment of chronic hepatitis B]. (2004) (4)
- 501 CLINICAL, VIROLOGICAL, SEROLOGICAL AND HISTOLOGICAL OUTCOMES IN CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 5 YEARS (2012) (4)
- 866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C (2013) (4)
- Viral hepatitis: towards the eradication of HCV and a cure for HBV (2016) (4)
- Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort (2020) (4)
- Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil (2002) (4)
- 909 CHARACTERISTICS OF HBeAg-POSITIVE PATIENTS WITH HBsAg LOSS/SEROCONVERSION FOLLOWING TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2009) (4)
- Interferon‐gamma with peginterferon alpha‐2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI) (2013) (4)
- Tenofovir DF (TDF) showed superior antiviral efficacy to adefovir dipivoxil in a randomized, double-blind, study for the treatment of HBeAg-negative chronic hepatitis B (CHB) (2008) (4)
- 538 IMPROVED PREDICTIVE VALUE FOR SUSTAINED IMMUNE CONTROL IN PEGINTERFERON ALFA-2A (40KD) (PEGASYS)-TREATED HBEAG-POSITIVE PATIENTS USING COMBINED HBSAG AND HBV DNA LEVELS AT WEEK 24 (2012) (4)
- Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort (2019) (4)
- Sustained Virological Response after 14 - D Ay Treatment with Danoprevir and 48-Week Treatment with Pegylated Interferon-α2A (40 Kd) plus Ribavirin (2012) (4)
- Pegeinterferon alfa-2a (40 KD) (Pegasys) plus ribavirin (copegus) is an efficacious and safe treatment for chronic hepatitis C (CHC) in patients with compensated cirrhosis (2003) (4)
- 809 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH ERADICATION OF HEPATITIS C VIRUS AND DECREASE IN ANTI-HCV TITER IN PATIENTS TREATED FOR CHRONIC HEPATITIS C (2008) (4)
- Cheating in scientific publishing: the scourge must stop! (2008) (4)
- 530 HIGH EFFICACY AND SAFETY OF TENOFOVIR DF IN 441 NAIVE AND NUC-EXPERIENCED CHRONIC HEPATITIS B PATIENTS: A REAL LIFE MULTICENTER PROSPECTIVE COHORT STUDY (2012) (4)
- [508] IN HEPATITIS B PATIENTS TREATED WITH EITHER ADEFOVIR OR TELBIVUDINE, MAXIMAL EARLY HBV SUPPRESSION AT 24 WEEKS PREDICTS OPTIMAL ONE-YEAR EFFICACY (2007) (4)
- Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study. (2015) (4)
- 774 BASELINE AND ON-TREATMENT FACTORS ASSOCIATED WITH HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH AND WITHOUT CIRRHOSIS FOLLOWING TREATMENT WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (2008) (4)
- 48 weeks of adefovir dipivoxil (ADV) results in improvement in fibrosis and decreased progression of fibrosis in a double-blind, randomized, placebo-controlled study for the treatment of patients with HBeAg plus chronic hepatitis B. (2002) (4)
- HCV infection assessed with third generation anti-HCV testing and polymerase chain reaction (1993) (4)
- Hepatitis C: The role of new interferons in the era of STAT-C (2009) (4)
- A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection (2003) (4)
- 451 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: ANALYSES OF PRE-DEFINED SUBPOPULATIONS IN THE PHASE 3 ADVANCE TRIAL (2011) (4)
- P677 HEPATIC STEATOSIS DOES NOT PREDICT REGRESSION OF LIVER CIRRHOSIS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2014) (4)
- P1127 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN TREATMENT-NAIVE EUROPEAN PATIENTS IN THE QUEST-1 AND QUEST-2 PHASE III TRIALS (2014) (4)
- A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy (2014) (3)
- [Treatment of chronic hepatitis B]. (2011) (3)
- 1017 EFFICACY OF TENOFOVIR DF TREATMENT IN PATIENTS WITH A SUBOPTIMAL RESPONSE TO ADEFOVIR DIPIVOXIL (2010) (3)
- 631 ASSESSMENT OF SERUM HCV-RNA AT WEEK 12 POST-TREATMENT IS AS RELEVANT AS WEEK 24 TO PREDICT SVR IN HCV PATIENTS RECEIVING PEGINTERFERON PLUS RIBAVIRIN (2009) (3)
- Treatment of viral hepatitis: a new era (2013) (3)
- Interferon-α therapy for chronic hepatitis C in special patient populations (1996) (3)
- [Natural history of hepatitis C virus infection]. (1995) (3)
- Long term course and prognostic factors in HCV-related compensated cirrhosis (1998) (3)
- 797 EASY TO ASSESS ON-TREATMENT PARAMETERS CORRELATE WITH DEGREE OF VIROLOGICAL RESPONSE AFTER 12 WEEKS OF TREATMENT (2008) (3)
- Authorship: pride and proliferation (2009) (3)
- Epidemiological, clinical, biological and virological factors influencing the occurrence of hepatocellular carcinoma and validation of predictive scores in 317 HBV-related cirrhotic patients. Prospective study Cir-B nested in the ANRS CO12 CirVir cohort (2016) (3)
- Targeted long read sequencing reveals the comprehensive architecture and expression patterns of integrated HBV DNA in CHB liver biopsies (2020) (3)
- Adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and clinical status regardless of baseline knodell fibrosis score in patients with HBeAg+Chronic hepatitis B (2003) (3)
- Above and beyond the Playing Field: An Interview with Hines Ward, NFL Wide Receiver (2007) (3)
- 1024 EFFICACY AND SAFETY OF THE COMBINATION OF ENTECAVIR (ETV)-TENOFOVIR (TDF) IN THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A NATIONWIDE, RETROSPECTIVE STUDY (2010) (3)
- 78 VALIDATION OF CONTROLLED ATTENUATION PARAMETER (CAP) AS A NON-INVASIVE MARKER OF STEATOSIS IN 228 PATIENTS WITH CHRONIC LIVER DISEASE FROM VARIOUS CAUSES (2010) (3)
- Liver cell proliferation in patients with chronic hepatitis C is reduced by interferon therapy (2000) (3)
- Anamnesis and diagnosis of hepatitis C (2006) (3)
- [Treatment of hepatitis C: advances and consensus]. (2002) (3)
- How to write a paper: an editor's tips (2008) (3)
- Recent advances in hepatology (2017) (3)
- [Hepatitis B: clinical application of HBsAg quantification]. (2013) (3)
- 508 IS HBEAG LOSS ASSOCIATED WITH AN IMPROVED OUTCOME IN HEPATITIS B PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2012) (3)
- The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection (2015) (3)
- T-25 Impact of insulin resistance on antiviral efficacy of telaprevir-based regimen in treatment-naïve genotype 1 HCV: Results from C208 sub-analysis (2011) (3)
- T2003 On-Treatment Response-Guided Therapy With Telaprevir Q8h or Q12h Combined With Peginterferon Alfa-2a or Peginterferon Alfa-2B and Ribavirin in Treatment-NaïVE Genotype 1 Hepatitis C (Study C208) (2010) (3)
- P0328 : Incidence, characteristics and determinants of primary liver cancer occurring during surveillance of compensated HCV cirrhosis according to sustained virological response (ANRS CO12 CirVir) (2015) (3)
- Improved predictive value for sustained immune control in peginterferon alfa-2a (40KD) (PEGASYS)-treated HBeAg-positive patients using combined HBsAg and HBV DNA levels at week 24 (2012) (3)
- 160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results (2008) (3)
- 1192 HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS (2012) (3)
- Factors associated with rapid progression of fibrosis following liver transplantation for hepatitis C (2003) (3)
- IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB) (2020) (3)
- [Liver, biliary tracts and human immunodeficiency virus infection. 2: hepatobiliary complications of AIDS]. (1996) (3)
- Prospective Evidence That Hepatocellular Carcinoma Surveillance in Patients with Compensated Viral Cirrhosis Increases the Probability of Curative Treatment and Survival Taking into Account Lead-Time Bias (Anrs Co12 Cirvir Cohort) (2016) (3)
- Journals' impact and pecking order: tyranny and tyrannosaurs (2012) (3)
- [21] INSULIN RESISTANCE IN 424 CHRONIC HEPATITIS C PATIENTS: ASSOCIATION WITH HCV REPLICATION AND ADVANCED FIBROSIS (2007) (3)
- Post treatment histologic outcome in patients with chronic hepatitis C treated with recombinant alpha interferon (1993) (3)
- Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study (2017) (3)
- [Hepatitis C and liver transplantation: fibrosis progression and treatment. Or how to improve management]. (2006) (3)
- [740] ASSESSMENT OF LIVER FIBROSIS USING LIVER STIFFNESS MEASUREMENT (LSM) IN PATIENTS WITH ALCOHOLIC LIVER DISEASE (2007) (3)
- CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years (2006) (3)
- Early negative tests for serum HCV RNA as a predictor of sustained response to interferon therapy in patients with chronic hepatitis C (1997) (3)
- Intra-portal lymphoid nodules: A histologic lesion distinctive of chronic hepatitis C (1991) (3)
- The power of one and saving private Braillon (2012) (3)
- No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B (2018) (3)
- P0468 : Negative impact of HBV/HCV coinfection on HBV or HCV monoinfection: Data from the French cohort – ANRS CO22 hepather (2015) (3)
- [Interferons. Structure, functions and therapeutic applications of interferons]. (1993) (3)
- The impact of direct antiviral agent therapy on liver fibrosis in patient with advanced fibrosis related chronic hepatitis C (2018) (3)
- “Total HCV core antigen assay”: a new marker of viremia and it's application in diagnosis (2002) (3)
- factors Associated with the Lack of Achievement of Normal Alt in Chronic Hepatitis B (chb) Patients Treated with Tenofovir Df (tdf) for up to 5 Years : 411 (2012) (3)
- Lack of mother to infant transmision of the hepatitis C virus (HCV) (1990) (2)
- 748 VIROLOGICAL RESPONSE AND TOLERANCE OF TENOFOVIR DF (TDF) IN THE ELDERLY IS SIMILAR TO YOUNGER PATIENTS IN REAL LIFE PRACTICE (2013) (2)
- Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis (2018) (2)
- [Assessment of hepatitis C networks]. (2002) (2)
- 806 TYPE OF RESPONSE TO PRIOR PEGYLATED INTERFERON ALFA-2B (12KD)/RBV PREDICTS SUBSEQUENT RESPONSE TO RETREATMENT WITH PEGINTERFERON ALFA-2A (40KD)/RBV (2008) (2)
- Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study (2019) (2)
- Corrigendum to “Resistance to adefovir: A new challenge in the treatment of chronic hepatitis B” [J Hepatol 43 (2005) 920–923] (2006) (2)
- 776 PATIENT EDUCATION IMPROVES ADHERENCE TO PEGINTERFERON AND RIBAVIRIN IN CHRONIC GENOTYPE 2 OR 3 HEPATITIS C VIRUS (HCV) INFECTION IN THE REAL-LIFE (2008) (2)
- 322 Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil (2009) (2)
- Gens Una Sumus (2007) (2)
- Corrigendum to “Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?” [J Hepatol 47 (2007) 580–587] (2008) (2)
- Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. (2006) (2)
- [Management of chronic hepatitis C in 2008]. (2008) (2)
- Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials (2020) (2)
- Efficacy and Neurotoxicity of ARA‐AMP in CAH‐B (1990) (2)
- [Pretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B]. (1998) (2)
- Staging Fibrosis in Chronic Viral Hepatitis (2022) (2)
- Relationship between anti-HCV antibodies measured by a quantitative riba assay and response to interferon in patients with chronic non A non B hepatitis (1991) (2)
- Recombinant alpha interferon therapy for chronic hepatitis C in anti-HIV positive patients (1991) (2)
- Gens Una Sumus – still (2013) (2)
- 436 Models to predict inflammation and fibrosis in patients with chronic hepatitis B (2004) (2)
- P1084 PRESENCE OF STEATOSIS AND HBeAg-POSITIVE STATUS ARE INDEPENDENTLY ASSOCIATED WITH PERSISTENTLY ELEVATED SERUM ALT LEVELS IN CHRONIC HBV PATIENTS DURING ANTIVIRAL THERAPY (2014) (2)
- Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterferon alpha-2a Plus Ribavirin and the Benefit-Risk Ratio of Retreatment (2013) (2)
- [Type II mixed cryoglobulinemia with cutaneo-nervous vasculitis during chronic hepatitis C]. (1991) (2)
- Safety and efficacy of peginterferon alpha-2b plus ribavirin in pre-cirrhotic and cirrhotic patients with chronic hepatitis C (2003) (2)
- Lack of benefit of prolonging interferon therapy in patients with chronic hepatitis C without early response (1998) (2)
- ‘Foie cardiaque’: a new name for an old syndrome? (2008) (2)
- 782 HEPATIC MIRNA SIGNATURE PREDICTING SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (2011) (2)
- Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B (2020) (2)
- [Unexpected protective role of interferon-alpha against Mycobacterium tuberculosis during the course of hepatitis C antiviral therapy]. (2004) (2)
- Relationship between the effector T-cell response and viremia in symptomatic chronic hepatitis C. (1998) (2)
- 15 TELAPREVIR (TVR) q8h OR q12h COMBINED WITH EITHER PEGINTERFERON (PEG-IFN, P) ALFA-2A OR ALFA-2B AND RIBAVIRIN (RBV, R) IN TREATMENT-NAÏVE GENOTYPE 1 HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY C208 (2010) (2)
- [Hepatitis C: the recovery]. (2009) (2)
- 1156 48 weeks of adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and virological status regardless of baseline knodell fibrosis score in patients with HBEAG- chronic hepatitis B (2003) (2)
- Sustained response to interferon therapy in patients with chronic hepatitis C (1993) (2)
- Influence of chronic HIV infection on chronic hepatitis B-delta in intravenous drug addicts (1991) (2)
- Sa1046 Efficacy of 5 Years of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients With High Viral Load (HBV DNA=9 Log10 Copies/Ml) (2012) (2)
- 761 COMPARISON OF SERUM HBsAg DECLINES DURING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN DIFFERENT CHRONIC HEPATITIS B (CHB) SUB-POPULATIONS (2013) (2)
- Whole-genome deep sequencing of hepatitis B virus in chronic hepatitis B patients reveals single nucleotide variants associated with baseline HBV DNA levels and HBeAg status (2017) (2)
- 833 LIVER FIBROSIS ASSESSMENT IN CHRONIC HEPATITIS C: EVOLUTION OF CLINICAL PRACTICE IN A LARGE COHORT OF 4546 PATIENTS BETWEEN 2003 AND 2006 (2008) (2)
- P.104 Durability of HBeAg seroconversion following adefovir dipivoxil treatment for chronic hepatitis B (CHB) (2006) (2)
- Towards the eradication of hepatitis C virus (2012) (2)
- 73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY (2012) (2)
- 283 HCV PROTEASE INHIBITOR RESTORES INSULIN SENSITIVITY IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2010) (2)
- 739 ALT FLARES DURING TREATMENT WITH PEGINTERFERON LAMBDA OR PEGINTERFERON alfa IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B INFECTION (CHB) (2013) (2)
- [Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives]. (1995) (2)
- 41 S-Collate COHORT ‘REAL-LIFE’ STUDY: EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN 1233 PATIENTS WITH CHRONIC HEPATITIS B ACCORDING TO ASIAN AND CAUCASIAN RACE (2013) (2)
- “Rebound” phenomenon after cessation of interferon therapy in chronic Non-A, Non-B (NANB) hepatitis (1990) (2)
- 635 INSULIN RESISTANCE AND GEOGRAPHICAL ORIGIN ARE MAJOR PREDICTORS OF LIVER FIBROSIS AND RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN IN GENOTYPE 4 CHRONIC HEPATITIS C PATIENTS (2009) (2)
- Detrimental influence of HIV on the natural history and the interferon (IFN) response rate in patients with chronic hepatitis B (CHB) (1998) (2)
- [Vidarabine treatment of chronic active hepatitis associated with hepatitis B virus multiplication. A randomized multicenter study]. (1987) (2)
- 529 WEEK 12 HBSAG TITER DECLINE IS PREDICTIVE OF SVR IN CHRONIC HEPATITIS B PATIENTS RECEIVING PEGYLATED INTERFERON PLUS TENOFOVIR COMBINATION THERAPY (2012) (2)
- A Simple Atmosphere Generating System for Experimental Storage of Fruits and Vegetables (1982) (2)
- 595 Evidence for eradication of HCV, assessed with transcription mediated amplification (TMA), in chronic hepatitis C patients with sustained virological response to therapy (2006) (2)
- 452 EFFICACY AMONG NORTH AMERICAN AND EUROPEAN HCV GENOTYPE-1 TREATMENT-NAIVE AND PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (2)
- Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF) (2017) (2)
- 571 More rapid drop of HCV RNA level under therapy and better sustained response rate in Egyptian patients versus non-Egyptian patients with HCV genotype 4 (2006) (2)
- IDDF2018-ABS-0105 No resistance to TENOFOVIR ALAFENAMIDE detected through 96 weeks of treatment in patients with chronic hepatitis B (2018) (2)
- Things fall apart with hepatocellular carcinoma and direct-acting antivirals (2018) (2)
- 20 THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE AND POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102 AND STUDY 103) (2010) (2)
- 783 DIFFERENTIAL LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C PATIENTS AT EARLY STAGES OF LIVER FIBROSIS (2011) (1)
- The severity of histologic lesions is not related to liver HCV RNA level in patients with chronic hepatitis C (1998) (1)
- Characterization of serologic responses following ALT flares in >3000 CHB patients pooled from 5 clinical trials (2020) (1)
- 390 TRENDS IN EPIDEMIOLOGICAL AND CLINICAL CHARACTERISTICS OF HCV-INFECTED PATIENTS OVER SIX YEARS: A FRENCH EXPERIENCE (2009) (1)
- Relationship between antiviral therapy responses and hepatic venous pressure gradient changes (2002) (1)
- Update on the Role of Quantitative HBsAg and HBeAg Monitoring during Peginterferon Therapy (2012) (1)
- Viral Suppression is Not a risk Factor for CKD in Viral Cirrhosis (ANRS CO12 CirVir Prospective Cohort) (2016) (1)
- [Interferons: structure, functions and therapeutic applications]. (1994) (1)
- Steatosis in chronic hepatitis C. Authors' reply (2006) (1)
- 390 DIAGNOSTIC PERFORMANCE OF TRANSIENT ELASTOGRAPHY IS SIMILAR IN HEPATITIS B AND HEPATITIS C PATIENTS (2010) (1)
- [487] PREDICTORS OF HBsAg REDUCTION IN HBsAg- NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) ALONE OR IN COMBINATION WITH LAMIVUDINE (2007) (1)
- [607] A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY ON ADHERENCE WITH VIRAL HEPATITIS C TREATMENTS (CHEOBS): IMPACT OF PAST PSYCHIATRIC DISORDERS ON SUSTAINED VIROLOGIC RESPONSE (SVR) (2007) (1)
- Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB) (2015) (1)
- [Treatment of chronic active hepatitis caused by hepatitis B virus infection]. (1988) (1)
- 591 A prospective, multicenter, observational study on compliance to hepatitis C treatments (CHEOBS): Characteristics of HCV-infected patients with psychiatric disorders (2006) (1)
- P776 REDUCTION OF MIR-122 IN IFNL3 CT+TT CARRIERS AND DURING PROGRESSION OF FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (2014) (1)
- Chronic HBV Infection: Interferon Therapy and Long-Term Outcomes (2018) (1)
- [509] WHICH PATIENTS WITH CHRONIC HEPATITIS B ARE TREATED AND HOW: A CROSS-SECTIONAL STUDY IN FRANCE ON 1790 PATIENTS (2007) (1)
- P0665 : HBV variants present in treatment naïve patients can predict response to NA therapy in immune clearance disease (2015) (1)
- 684 LIVER GENE EXPRESSION SIGNATURE TO PREDICT RESPONSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C (2010) (1)
- Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients (2016) (1)
- 491 Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B (CHB) (2006) (1)
- Quantification of HBV hepatocyte burden using novel multiplex immunofluorescence staining and image analysis reveals substantial reduction in HBV liver burden with anti-viral treatment (2022) (1)
- 497 FACTORS ASSOCIATED WITH REGRESSION OF CIRRHOSIS IN PATIENTS WITH CHORNIC HEPATITIS B (CHB) INFECTION TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2012) (1)
- 844 IMPACT OF ANTIVIRAL THERAPY ON SURVIVAL IN PATIENTS WITH ADVANCED FIBROSIS – EXPERIENCE OF BEAUJON HOSPITAL 2000 TO 2010 (2013) (1)
- 418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) (2011) (1)
- 1058 INSULIN RESISTANCE: A MAJOR PREDICTOR OF SIGNIFICANT LIVER FIBROSIS IN EGYPTIAN PATIENTS WITH GENOTYPE 4 CHRONIC HEPATITIS C (2010) (1)
- Impact of ribavirin dose on retreatment of chronic hepatitis C patients. (2012) (1)
- Identifying residual risk of hepatocellular carcinoma following hepatitis C virus eradication in compensated cirrhosis: decision-tree and random forest models developed in the French multicenter prospective ANRS CO12 CirVir cohort (2017) (1)
- 781 INCIDENCE AND PREDICTORS OF HCC IN CHRONIC HEPATITIS C PATIENTS WITH CIRRHOSIS AND NON RESPONDING TO PEGINTERFERON AND RIBAVIRIN THERAPY (2009) (1)
- 573 Long-term outcome of hepatitis C infection after bone marrow transplantation (2003) (1)
- [Treatment has a positive impact on the long-term evolution of chronic hepatitis B]. (2010) (1)
- Co-infection VIH-VHC en l'an 2001 (2001) (1)
- Economic analysis of early serum hepatitis C virus RNA testing in patients with chronic hepatitis C on interferon therapy. (2000) (1)
- Emergency transplantation for acute reactivation of chronic hepatitis B with high viral load: role of antiviral therapy (2009) (1)
- Durability of HBsAg loss with nucleotide analogs and pegylated interferon in patients infected with hepatitis B virus (2017) (1)
- Characteristics of HBeAg-positive patients chronically infectedwith hepatitis b virus (HBV) who achieved hbsag loss/seroconversion following tenofovir disoproxil fumarate (TDF) treatment (2009) (1)
- 947 Precore and core promoter mutations or serum HBV DNA levels do not allow to distinguish true inactive HBSAG carriers from HBEAG negative chronic hepatitis B with fluctuating ALT (2003) (1)
- Serum IL 10 in chronic hepatitis C (2000) (1)
- Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography (2017) (1)
- M1891 Quantitative HBsAg: A New Specific Marker for the Diagnosis of HBsAg Inactive Carriage (2010) (1)
- [Treatment of chronic hepatitis C with interferon alpha]. (1991) (1)
- 05E. VIRAL HEPATITIS – E) HEPATITIS B – CLINICAL (THERAPY, NEW COMPOUNDS, RESISTANCE) S259 694 MDRD CREATININE CLEARANCE IS NOT ALTERED IN HIV-HBV CO-INFECTED PATIENTS WITH A NORMAL RENAL FUNCTION AND TREATED WITH TENOFOVIR (2008) (1)
- 8 Chronic viral hepatitis (2003) (1)
- Impact of the Use of Drugs and Substitution Treatments on the Antiviral Treatment of Chronic Hepatitis C: Analysis of Compliance, Virological Response and Quality of Life (CHEOBS) (2009) (1)
- 1159 Lack of ethnic differences in response to adefovir dipivoxil therapy in HBEAG+ and HBEAG- patients with chronic hepatitis B (2003) (1)
- Evaluation of trugene HBV genotyping kit (research only), a sequence based genotyping assay for determination of mutations and viral genotype (2003) (1)
- [Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses]. (1996) (1)
- Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells (2022) (1)
- 447 IL28B POLYMORPHISM IS NOT ASSOCIATED WITH RESPONSE TO CONVENTIONAL INTERFERON TREATMENT AND HBSAG SEROCLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS (2012) (1)
- 754 QUASISPECIES ANALYSIS OF HBV STRAINS ISOLATED FROM CHRONIC HEPATITIS B PATIENTS TREATED WITH PEG-INTERFERON+ TENOFOVIR THERAPY (2013) (1)
- 777 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH A LOWER RISK OF COMPLICATIONS AND HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HCV RELATED CIRRHOSIS (2008) (1)
- Contribution of nucleic acid amplification techniques to the safety of blood components in France (1998) (1)
- 808 ASSESSMENT OF VIROLOGICAL RESPONSE AT BOTH WEEK 4 AND WEEK 12 OPTIMIZES PREDICTION OF PEGINTERFERON ALFA PLUS RIBAVIRIN.TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (2008) (1)
- Prise en charge de l'hépatite chronique B. Recommandations des pratiques cliniques EASL (European Association for the Study of the Liver) (2010) (1)
- Long-Term Risk of Hepatocellular Carcinoma during Follow-Up of Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase (2016) (1)
- Baseline HBsAg and HBcrAg Titers Allow Peginterferon Based “Precision Medicine” in Hbeag-Negative Chronic Hepatitis B (2016) (1)
- Serum tumor necrosis factor level in chronic hepatitis C (2001) (1)
- Long-Term Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B with Normal Alanine Aminotransferase (2018) (1)
- PF-03491390 INHIBITS LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION VIA SUPPRESSION OF PRO-APOPTOTIC CASPASE-ACTIVA- TION. (2007) (1)
- P0644 : HCC risk scores: Application of the CU-HCC, GAG-HCC and page-B scores to chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF) (2015) (1)
- Editor's report: reflections on the first year (2008) (1)
- Treatment of chronic non-A, non-B hepatitis with recombinant alpha interferon: Comparison between constant and increasing dosage (1991) (1)
- Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B (2022) (1)
- 634 Assessment of biliary fibrosis by transient elastography in PBC and PSC patients (2006) (1)
- Management of chronic hepatitis C. (2007) (1)
- Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease (2012) (1)
- 925 SAFETY AND TOLERABILITY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBeAg NEGATIVE AND POSITIVE PATIENTS INFECTED WITH CHRONIC HEPATITIS B (CHB) (2009) (1)
- Effect of newer oral antiviral agents on future therapy of chronic hepatitis B (2010) (1)
- Comparison of effect of alfa interferon in italian patients with cryptogenetic chronic active hepatitis and in patients with posttransfusion chronic active hepatitis non A non B (1989) (1)
- 695 LOW RATE OF DELAYED RESPONSE IN LAMIVUDINE EXPERIENCED HIV/HBV CO-INFECTED PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) (2008) (1)
- Early virologic response (EVR) at week 8 is more predictive of sustained response (SR) to pegylated combination therapy than at week 12 (2003) (1)
- Chronic Non-A, Non-B, Non-C Hepatitis in French Blood Donors Assessed with HCV Third-generation Tests and Polymerase Chain Reaction (1994) (1)
- Long-term Histologic Improvement and Persistent HCV Replication in Patients with Chronic Hepatitis C Having Responded to Recombinant Alpha Interferon (1994) (1)
- [What does chronic hepatitis C steatosis mean?]. (2003) (1)
- Dealing with editors: ‘nice n’ easy does it every time’ (2012) (1)
- Hypervariable region 1 quasispecies in chronic hepatitis C patients: influence of genotype (2001) (1)
- 23 The effect of peginterferon alfa-2a (40KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (MIPD) (2003) (0)
- 375 Basal core promotor (BCP) and precore mutations, HBV genotype or serum HBV DNA levels do not allow to distinguish true inactive HBSAG carriers from HBEAG negative chronic hepatitis B with fluctuating alt (2004) (0)
- enofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated atients With Chronic-Hepatitis B Virus Infection (0)
- The Presence of BCP/PC Variants Reduces the Rate of HBsAg Loss among HBeAg-Positive CHB Patients Treated with Long-Term Tenofovir DF Therapy (2016) (0)
- W1814 Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB) (2009) (0)
- Hepatitis C case report (2006) (0)
- Sa1495 - Hbeag Loss and Seroconversion Predictors by Baseline Clinical Features and Viral Deep Sequencing of Treatment with Tenofovir Alafenamide Fumarate (TAF) or Tenofovir Disoproxil Fumarate (TDF) after 144 Weeks (2018) (0)
- P.259 Retreatment with peginterferon alpha-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients in whom pegylated interferon alpha-2b (12KD)/ribavirin has failed: planned week-12 efficacy and safety analysis of the repeat study (2006) (0)
- 533 Rantes as a immune resonse to inflammation in chronic hepatitis C (2004) (0)
- Peginterferon, Ribavirin and Anti-viral Triple Therapy (2012) (0)
- Serum HBV DNA level and liver histology in healthy HBSAG carriers (2001) (0)
- Efficacy Among North American and European HCV Genotype-1 Treatment-NaïVE and Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (0)
- Traitement de l’hépatite chronique B Treatment of chronic hepatitis B (2008) (0)
- [Clinical picture and evolution of hepatitis C]. (1996) (0)
- Whole-genome sequencing of patients achieving hepatitis B virus serum antigen loss following tenofovir disoproxil fumerate (TDF) and/or pegylated-interferon α-2a (PEG) therapy (2017) (0)
- 1170 Kinetics of viral resistance and serum HBV DNA in patients underlamivudine therapy (2003) (0)
- Reply: (2007) (0)
- 163 Underestimated impact of alcohol consumption on the progression of fibrosis in patients transplanted for HCV related cirrhosis: A comparative study with patients transplanted for alcohol-related cirrhosis (2006) (0)
- Hepatitis B virus Resistance to Antivirals : Diagnosis and Management (2011) (0)
- P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin (2006) (0)
- Natural history of the hepatitis C (1999) (0)
- Role of HIV and HCV infections on chronic hepatitis B in homosexual men (1991) (0)
- 1147 VIROLOGICAL RESPONSE AND RELAPSE RATES IN FRENCH CHC PATIENTS TREATED WITH PEGINTERFERON ALFA-2A/RIBAVIRIN: A SUB-ANALYSIS OF THE FINAL POPULATION FROM THE PROPHESYS STUDY (2012) (0)
- 421 FIB-4 SCORE IS A STRONGER PREDICTOR OF VIROLOGICAL RESPONSE THAN LIVER BIOPSY (METAVIR) IN HEPATITIS C GENOTYPE 1 PATIENTS: INTERIM DATA FROM THE PROPHESYS TRIAL (2011) (0)
- Total HCV core antigen assay: a surrogate marker of viral replication and it's use in monitoring response to therapy (2002) (0)
- Retraitement par interferon alpha recombinant des patients atteints d'hépatite chronique C (1992) (0)
- Interféron et hépatite chronique non-A, non-B : état de la question (1991) (0)
- Detection of hepatitis B surface antigen by a monoclonal radioimmunoassay in the serum of alcoholic patients (1988) (0)
- [Hepatitis C, cirrhosis and hepatocellular carcinoma]. (2008) (0)
- Pleasing and displeasing things (2010) (0)
- Reply (2011) (0)
- 778 SUSTAINED VIROLOGICAL RESPONSE IS ASSOCIATED WITH REVERSIBILITY OF CIRRHOSIS IN CHRONIC HEPATITIS C PATIENTS (2008) (0)
- PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE (2009) (0)
- O.164 Eradication of HCV and regression of fibrosis, in chronic hepatitis C patients with sustained virological response to therapy (2006) (0)
- 820 A FOUR GENE MOLECULAR SIGNATURE IS BETTER THAN IL28B POLYMORPHISM TO PREDICT TREATMENT RESPONSE TO PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C (2012) (0)
- Similarities and Differences Between REPEAT and EPIC3. Authors' reply (2009) (0)
- Risks of Liver Complications after a Long-Term Follow-Up in Patients with Chronic Hepatitis C with Sustained Virologic Response (2016) (0)
- Treatment of chronic hepatitis B: an update (2005) (0)
- Tenofovir Disoproxil Fumarate (TDF) Use in HIV/HBV Co-Infected Patients in the Setting of Decompensated Liver Disease (Dld): Retrospective Evaluation of Eight Cases (2008) (0)
- Risk Factors and Characteristics of Hepatocellular Carcinoma Occuring in HCV Cirrhotic Patients after Sustained Virological Response (2016) (0)
- Innovative Well Testing System for High-Rate Sour-Gas Khuff Well in the North Field, Qatar (2006) (0)
- Similarities and Differences Between REPEAT and EPIC3 (2009) (0)
- OP11 Final results from telaprevir phase II studies in genotype 1 treatment-naive or experienced subjects with chronic hepatitis C (2010) (0)
- P1062 3-YEAR TREATMENT WITH TENOFOVIR IN REAL-LIFE IS EFFECTIVE AND WELL TOLERATED IN CHB PATIENTS, INCLUDING THE ELDERLY AND PATIENTS WITH COMORBIDITIES (2014) (0)
- Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir (2020) (0)
- 302 IMPACT OF A HIGH RIBAVIRIN DOSE PER WEIGHT ON RESPONSE TO RETREATMENT AFTER RELAPSE TO PEGYLATED INTERFERON PLUS RIBAVIRIN (2010) (0)
- [Hepatitis C virus infection and pregnancy]. (1992) (0)
- Erratum: Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial (Lancet (2014) 384 (403-13)) (2016) (0)
- Machine learning identifies histologic features associated with regression of cirrhosis in treatment for chronic hepatitis B (2020) (0)
- [Hepatitis C in 2007...progress and challenges]. (2007) (0)
- 1149 REDUCTION OF mir-122 EXPRESSION IN IL28B CT/TT CHRONIC HEPATITIS C PATIENTS WHO FAILED TO PEGYLATED-INTERFERON PLUS RIBAVIRIN TREATMENT (2013) (0)
- Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB) (2009) (0)
- Interferon-α in chronic hepatitis C [1] (multiple letters) (1998) (0)
- Title page (2016) (0)
- P.003 Clinical relevance of the COBAS TaqMan HBV assay (2006) (0)
- The Benefits of Virosuppression on Progression of Portal Hypertension in Patients with Compensated Viral Cirrhosis (ANRS CO12 CirVir Cohort) (2016) (0)
- P.245 Genotype and fibrosis stage are major predictors of sustained virological response to retreatment with pegylated combination in non-responders to standard combination therapy (2006) (0)
- Adefovir dipivoxil 10 mg (ADV) results in consistent efficacy in chronic hepatitis B (CHB) patients with diverse baseline characteristics (2003) (0)
- 112 INCIDENCE AND PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA AND COMPLICATIONS IN HBV- OR HCV-RELATED COMPENSATED CIRRHOSIS. A MULTICENTER PROSPECTIVE COHORT IN 1653 PATIENTS (ANRS CO12 CirVir) (2013) (0)
- Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) (2003) (0)
- [New management strategies for hepatitis B]. (2002) (0)
- Recombinant alpha interferon in patients with decompensated cirrhosis related to HBV (1991) (0)
- P0657 : Adding tenofovir to Pegylated Interferon enhances end of treatment HBsAg loss in HBeAg negative chronic hepatitis B patients (2015) (0)
- HBsAg Loss With TDF Plus PegIFN in Chronic Hepatitis B (CHB): Long-term Results of a Global Randomized Controlled Trial (2017) (0)
- [Treatment of chronic viral hepatitis]. (1992) (0)
- S1938 HCV-RNA Status At Week 12 of Treatment with Peginterferon Alfa-2a/RBV Predicts SVR in Patients with Prior Non-Response to Pegylated Interferon Alfa-2b/RBV: Results from Repeat Study (2008) (0)
- T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies (2010) (0)
- P0523 : Modification of expression of MIR-20A, MIR-92A and MIR-122 during fibrosis in patients with chronic hepatitis C (2015) (0)
- T2000 Liver Gene Expression Signature to Predict Response to Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C (2010) (0)
- 320 COMPETITION BETWEEN DIVERGENT HEPATITIS C VIRUS STRAINS DRIVEN BY INTERNAL RIBOSOME ENTRY SITE EFFICIENCY IN LIVER AND B-CELLS (2009) (0)
- P0800 : Effectiveness and safety of combination new regimens based on Sofosbuvir (SOFO) with Ribavirin (RBV), Daclatasvir (DAC) or Simeprevir (SIM) in difficult patients to treat infected with chronic hepatitis C (CHC) (2015) (0)
- O.139 Two types of histologically normal liver can have different gene expression patterns: The importance of an adequate normal tissue control in gene expression studies (2006) (0)
- 391 ABSENCE OF INFLUENCE OF METABOLIC FACTORS ON DIAGNOSTIC PERFORMANCE OF LIVER STIFFNESS MEASUREMENT IN CHRONIC HEPATITIS B AND C (2010) (0)
- S1941 Easy to Assess On-Treatment Parameters Correlate with Degree of Virological Response After 12 Weeks of Treatment (2008) (0)
- Viral hepatitis in 2011: a major step forward (2011) (0)
- Extrahepatic Cancer is the Second Cause of Non Liver-Related Death in Patients with Compensated Viral Cirrhosis and is Associated with Viral Replication (ANRS CO12 CirVir Prospective Cohort) (2016) (0)
- O.193 Internal ribosomal entry site (IRES)-dependent tropism of hepatitis C virus (2006) (0)
- Hepatocellular carcinoma (HCC) scoring system for the individualized prediction of liver cancer in 1080 HCV-related compensated cirrhosis included in the French multicenter prospective cohort ANRS CO12 CirVir (2015) (0)
- 834 REDUCTION OF MIR-122 EXPRESSION IS ASSOCIATED WITH IL28B RS12979860 TT POLYMORPHISM AND IS INDEPENDENT OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C (2012) (0)
- A critical study of peirasmos in James and its implications for han in Minjung theology in light of Kierkegaard's three-stage model (2009) (0)
- 1215 Multivariate models predict outcome to hepatitis C virus therapy at baseline and at weeks 4 and 8 (2003) (0)
- Reply (1993) (0)
- 392 LIVER STIFFNESS IS ASSOCIATED WITH CLINICAL OUTCOME OF HCV RELATED CIRRHOSIS (2009) (0)
- Demonstration of hepatitis B virus DNA using polymerase chain reaction in serum and liver after loss of HBs Ag induced by antiviral therapy (1989) (0)
- 827 EFFICACY OF PEGINTERFERON ALPHA-2a AND RIBAVIRIN IN HIV/HCV CO-INFECTED PATIENTS: SUBANALYSIS OF HEPATYS, FRENCH NATIONAL SURVEY (2008) (0)
- 2010: reflections, changes and ghosts (2010) (0)
- Therapeutic options for chronic hepatitis B in 2013 (2013) (0)
- [Genetic variability of the hepatitis C virus: clinical implications]. (2000) (0)
- [Interferon and chronic non-A, non-B hepatitis: status of the problem]. (1991) (0)
- [Treatment of hepatitis B]. (2002) (0)
- Precore and Basal Core Promoter Mutants Improve the Diagnostic Performance of Fibroscan® or Fibrotest® to Predict Significant Fibrosis in Chronic Hepatitis B Patients (2016) (0)
- 634 IMPACT OF THE DRUG USE AND SUBSTITUTION TREATMENTS ON THE ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C: ANALYSIS OF ADHERENCE, VIROLOGICAL RESPONSE AND QUALITY OF LIFE (2009) (0)
- Efficacy, Safety and UK Cost-Effectiveness in Treatment-Naive Patients with F2 Fibrosis Treated with Telaprevir (TVR; T) in Combination with Peginterferon (P) and Ribavirin (R) vs Peginterferon and Ribavirin Alone: 428 (2012) (0)
- P0626 : The analysis of the expression of A2M, COL1A1, MMP2 and CHI3L identifies significant fibrosis in patients with chronic hepatitis B (2015) (0)
- Interferon for HBeAg-negative chronic hepatitis B: Teaching an old trick to an old dog? (2005) (0)
- Treatment of chronic viral hepatitis. (1992) (0)
- Installation measures for rupture tests blade of a turbomachine (2012) (0)
- Chapter 20. Treatment of Chronic Hepatitis B (2007) (0)
- Predictors of HBeAg loss and seroconversion by baseline clinical features and viral deep sequencing after 144 weeks of treatment with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate (2018) (0)
- [Clinical aspects of infection by non-A, non-B hepatitis (C) virus]. (1990) (0)
- Hypervariable region 1 (HVR 1) quasispecies outcome in patients with chronic hepatitis C (2001) (0)
- 412 THE USEFULNESS OF DEFINING RVR BY A VERY SENSITIVE ASSAY DURING THE TREATMENT OF HCV GENOTYPE 3 INFECTION; A COMPARISON OF TMA AND AMPLICOR (2011) (0)
- [Treatment of patients with chronic hepatitis C who have not been previously treated]. (2002) (0)
- 802 IMPACT OF PSYCHIATRIC DISORDERS ON ADHERENCE TO TREATMENT, QUALITY OF LIFE AND VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2008) (0)
- Relevance of total HCV core antigen testing for monitoring and predicting patients response (2002) (0)
- Measuring serum HCV RNA in clinical samples : a specificity and sensitivity study (1998) (0)
- Effect of zidovudine on hepatitis B virus (HBV) replication in patients with chronic HIV and HBV infection (1989) (0)
- FRI-149-Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients (2019) (0)
- P0768 : Late mortality in treatment-experienced cirrhotic patients treated with triple therapy including boceprevir or telaprevir in a real-life cohort - ANRS Co 20 cupic (2015) (0)
- Usefulness of the SAF score to characterize NAFLD/NASH in non-cirrhotic HCV patients (2022) (0)
- RECENT ADVANCES IN CLINICAL PRACTICE STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER? (2005) (0)
- Liver steatosis is not associated with fibrosis in patients with chronic HCV infection (2003) (0)
- Hepatitis B and D (2006) (0)
- 410 Gene expression profiling of liver fibrosis in patients with hepatitis C virus chronic infection using a large scale real-time RT-PCR approach (2003) (0)
- 388 Gene expression profiling of liver fibrosis in patients with chronic HCV infection using a large scale real-time RT-PCR approach (2004) (0)
- 635 Efficacy and Safety of the Combination of Entecavir (ETV)-Tenofovir (TDF) in the Treatment of Chronic Hepatitis B (CHB): A Nationwide, Retrospective Study (2010) (0)
- 420 INFLUENCE OF GENDER ON VIRAL LOAD ACCORDING TO AGE IN PATIENTS WITH CHRONIC HEPATITIS C: A POSSIBLE EFFECT OF HORMONAL FACTORS (2009) (0)
- Hepatitis C virus and transplantation. (2000) (0)
- P.009 Epidemiological characteristics of HBV inactive chronic carriers and comparison with hbe antigen negative chronic hepatitis B patients (2006) (0)
- P0579 : Epidemiological, clinical and virological features of hepatitis delta virus infection in France (2015) (0)
- O.048 Treatment of chronic hepatitis B with the combination of pegylated interferon with a nucleoside/nucleotide analogue (2006) (0)
- THU-205-Evaluation of HBV outcomes after treatment discontinuation from 4 phase 3 studies (2019) (0)
- P0656 : Add on peginterferon to adefovir enhances HBsAg loss in inactive HBV carriers (2015) (0)
- Randomised controlled trial of alfa interferon in chronic active hepatitis non A non B (1989) (0)
- 682 HBVDNA SUPPRESSION INDUCED BY PEGINTERFERON ALFA-2A (40KD) BUT NOT BY LAMIVUDINE RESULTS IN HBSAG LOSS AND SEROCONVERSION AT 3 YEARS POST-TREATMENT (2008) (0)
- PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES (2009) (0)
- P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
- [Treatment "à la carte" of chronic hepatitis B]. (2008) (0)
- A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV (2003) (0)
- Treating HBeAg-positive chronic hepatitis B (2003) (0)
- 316 IN VIVO ENDOPLASMIC RETICULUM STRESS IN PATIENTS WITH CHRONIC HEPATITIS C (2009) (0)
- [514] PREDICTION OF LIVER HISTOPATHOLOGY BY NON-INVASIVE MODELS IN HBeAg-POSITIVE AND HBeAg-NEGATIVE CHRONIC HEPATITIS B (2007) (0)
- [Management of chronic hepatitis in 2008]. (2008) (0)
- Impact of IL28B, APOH and ITPA Polymorphisms on Ecacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS (2016) (0)
- [Benign recurrent cholestasis]. (1985) (0)
- [Treatment of chronic hepatitis B]. (2004) (0)
- On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB (2017) (0)
- Safety of peginterferon alpha-2a (40KD) (PEGASYS (R)) [PEG-IFN alpha-2a (40KD)] plus ribavirin (COPEGUS (R)) among pegylated interferon alpha-2b (12KD)/ribavirin non-responders: Interim analysis of the repeat study (2006) (0)
- 835 GLOBAL ANALYSIS OF LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C LEADING TO A SIGNATURE TO PREDICT RESPONSE TO TREATMENT (2012) (0)
- 83 ALTERED EXPRESSION OF MICRORNAS (MIRNAS) IN LIVERS FROM PATIENTS WITH CHRONIC HEPATITIS C (2009) (0)
- Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients (2019) (0)
- Treatment of chronic hepatitis c. (2004) (0)
- Aspects cliniques de l'infection par le virus non-A non-B (C) (1990) (0)
- Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR) (2011) (0)
- 846 CHARACTERIZATION OF THE EARLY VIRAL KINETICS IN COMPENSATED CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS TREATED WITH BOCEPREVIR AND TELAPREVIR (2013) (0)
- 597 Genotype and fibrosis stage are major predictors of sustained virological response to retreatment with pegylated combination in non responders to standard combination therapy (2006) (0)
- P697 SERUM LEVELS OF HEPATITIS B SURFACE ANTIGEN (HBsAg) PREDICT HEPATIC FIBROSIS SEVERITY IN E ANTIGEN-POSITIVE CHRONIC HEPATITIS B (HBeAg+VE CHB) PATIENTS (2014) (0)
- Use of noninvasive biomarkers to assess fibrosis regression in cirrhotic patients during nucleos(t)ide therapy (2018) (0)
- Characterization of HBsAg decline by genotype in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumurate (TDF) for up to 4 years (2011) (0)
- T1958 Liver Gene Expression Signature of Mild Fibrosis in Chronic Hepatitis C (2010) (0)
- 738 HIGHEST RATES OF RESPONSE AT WEEK 72 OF THE NEPTUNE STUDY ARE ACHIEVED WITH PEGINTERFERON ALFA-2A 180 μG FOR 48 WEEKS (2011) (0)
- 575 Retreatment with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in pegylated interferon α-2b (12KD)/ribavirin non-responders with cirrhosis/advanced fibrosis: Repeat interim analysis (2006) (0)
- P0794 : Relationship between HCV genotype, liver co-morbidities and fibrosis in the French cohort ANRS CO22 HEPATHER (2015) (0)
- Early antiviral response to alpha interferon therapy in patients with chronic hepatitis C. Relationship with genotype and dose of interferon (1998) (0)
- 128 DIAGNOSTIC PERFORMANCE OF TRANSIENT ELASTOGRAPHY (FIBROSCAN) TO IDENTIFY PATIENTS ELIGIBLE FOR ANTIVIRAL TREATMENT IN CHRONIC HEPATITIS B (2011) (0)
- Short communication Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients (2009) (0)
- Efficacy of a second course of alpha interferon in patients with chronic hepatitis C (1994) (0)
- 632 MONITORING VIROLOGIC ON TREATMENT RESPONSE TO PREDICT TREATMENT OUTCOME IN PATIENTS WITH CHRONIC HEPATITIS C: REALTIME PCR ASSAYS AND BDNA/TMA PROVIDE THE SAME PERFORMANCES (2009) (0)
- 1083 FACTORS ASSOCIATED WITH FIBROSIS IN CHRONIC HEPATITIS C FEMALE PATIENTS: IMPACT OF MENOPAUSE (2010) (0)
- Chapter 23. Hepatitis C (2007) (0)
- Ultrasonic scaler: possible route for hepatitis C virus transmission (2002) (0)
- Hepatitis C: current status, future progress (1998) (0)
- Reply: (2009) (0)
- P0860 : The impact of interferon-free regimens on employment rate during treatment in patients with chronic hepatitis C (2015) (0)
- Interferon- in Chronic Hepatitis C (1998) (0)
- Apoptosis and tumor necrosis factor alpha levels in chronic hepatitis C parallel the histological activity index (2003) (0)
- A gentle life (2009) (0)
- P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] (2006) (0)
- Use of ARA-AMP in liver transplant patients with HBV graft infection (1991) (0)
- P0605 : Genotype specific variation in the basal core promoter and pre core regions impacts HBeAg levels during immune clearance disease (2015) (0)
- Safety and efficacy in lamivudine experienced chronic hepatitis B (CHB) patients treated for two years with tenofovir disoproxil fumarate (2009) (0)
- 620 IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S) (2009) (0)
- Treatment of chronic hepatitis B (2005) (0)
- 640 IN VIVO LIVER ENDOPLASMIC RETICULUM STRESS IN CHRONIC HEPATITIS C (2010) (0)
- 321 Safety and Efficacy of 96 Weeks of Tenofovir Disoproxil Fumarate Therapy in Lamivudine Experienced Patients (2009) (0)
- The assessment of liver fibrosis stage by two-dimensional shear wave ultrasound and Transient Elastography in patients with chronic liver disease (2017) (0)
- Efficacy of tenofovir disoproxil fumarate treatment in patients with a suboptimal response to adefovir dipivoxil (2010) (0)
- Asian patients with HBeAg-negative chronic hepatitisB respond well to peginterferon alfa-2a (40 KD)(PEGASYS®) treatment (2006) (0)
- Hepatitis B precore virus mutations and HBeAg negative reactivation after interferon therapy in chronic hepatitis B (1993) (0)
- Reply: (2008) (0)
- Current Management of Patients with HCV Genotype 1 (2021) (0)
- P.232 Egyptian patients have better sustained response and more rapid drop of HCV RNA level than non-Egyptian patients with HCV genotype 4 (2006) (0)
- Serum TNFA and TGF b levels in patients with chronic hepatitis C reflect the severity of the disease (2000) (0)
- Cytokine-chemokine signiture and severity of chronic hepatitis C (2003) (0)
- M1898 In Vitro Susceptibility of HBV Strains Isolated From HBV Patients With Primary Nonresponse to Adefovir (2010) (0)
- Observational study of patients treated for chronic hepatitis C in France (2003) (0)
- Is Interferon a Valuable First‐Line Therapy for HBeAg‐Positive HBV? (2010) (0)
- CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C (2008) (0)
- Responses to peginterferon alfa-2a (40KD) (PEGASYS) treatment are durable in Asian Patients with HBeAg-Negative CHB: 12 month Follow-Up Data from a large Randomised Study (2006) (0)
- P0610 : Dynamic prediction of inactive chronic hepatitis B using repeated HBsAg and HBV DNA level measurements through long-term follow-up (2015) (0)
- 820Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b (2014) (0)
- 1103 A 4 SERUM PROTEIN SIGNATURE FOR THE DIAGNOSIS OF MILD FIBROSIS IN CHRONIC HEPATITIS C (HEPACHRONIX STUDY) (2013) (0)
- 1171 Molecular epidemiology of hepatitis B virus in patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B from different geographical areas. Data from the PEGASYs® study in HBE-antigen-negative CHB (2003) (0)
- Predictors of progression of liver disease in chronic hepatitis C patients with minimal fibrosis: kinetic of serum tumor necrosis factor and transforming growth factor serum levels (2002) (0)
- Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease (2020) (0)
- INFLUENCE DE L'INFECTION HIV SUR L'HEPATITE NON-A NON-B CHEZ LES TOXICOMANES (1993) (0)
- Reply: (2007) (0)
- M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF) (2009) (0)
- 492 HBeAg and HBV DNA kinetics in HBeAg clearance with peginterferon alpha-2a (40KD) (PEGASYS) treatment for HBeAg-positive chronic hepatitis B (CHB) (2006) (0)
- 377 Evaluation of the realquant® HBV-DNA assay (realtime PCR) (2004) (0)
- [526] ROLE OF HIV COINFECTION IN MORTALITY RELATED TO HEPATITIS C AND HEPATITIS B IN FRANCE (2007) (0)
- 323 Two types of histologically normal liver can have marked difference in gene expression profiles: Importance of an adequate normal tissue control in gene expression studies (2006) (0)
- Health-Related Quality of Life (HRQL) and Health Utilities (HU) of Patients with Chronic Hepatitis C (CH-C) Treated with an Interferon (IFN)-Free Regimen Containing Ledipasvir (LDV) and Sofosbuvir (SOF): 568 (2014) (0)
- The effect of peginterferon alfa-2a (40 KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (2003) (0)
- HBV : Clinical Characteristics of Patients who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 288 Weeks of Therapy (2013) (0)
- [How should hepatitis C be treated? Treatment of hepatitis C with interferon]. (1997) (0)
- [Treatment of chronic hepatitis B]. (2006) (0)
- 387 HEPATITIS DELTA IN FRANCE: RESULTS IN 188 PATIENTS ON THE FRENCH HEPATITIS DELTA NETWORK (2011) (0)
- 542 THE ENTEBE STUDY: SAFETY AND EFFICACY OF ENTECAVIR PLUS TENOFOVIR IN ADULTS WITH CHRONIC HEPATITIS B AND PREVIOUS NUCLEOS(T)IDE TREATMENT FAILURE (2012) (0)
- INTERFERON-ALPHA IN CHRONIC HEPATITIS C. AUTHOR'S REPLY (1998) (0)
- [Chronic hepatitis B: which patients should be treated and how?]. (2005) (0)
- Chronic hepatitis B (2012) (0)
- ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts (2022) (0)
- PIN6 AN OBSERVATIONAL HEALTH ECONOMIC ANALYSIS OF THE COMBINED THERAPY WITH PEGINTERFERON ALPHA-2A (PEGASYS®) AND RIBAVIRIN IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) IN A REAL LIFE SETTING (2008) (0)
- 376 Evaluation of the increased sensitivity of the versant® HBV DNA 3.0 assay with serum samples routinely tested with cobas amplicor HBV monitor (2004) (0)
- Long-term follow-up of patients with chronic hepatitis(who showed nonresponse relapse or partial response after alpha interferon therapy (1999) (0)
- [Post-hepatitis B, B-D and C cirrhosis]. (1991) (0)
- Evaluation of the virological response during PEG-IFN/RIB treatment by HCV NAT or total HCV core AG testing leads to similar clinical decisions (2003) (0)
- Hepatitis B and Hepatitis C in 2004 (2004) (0)
- First European Young Hepatologist Workshop: topics and advances. (2011) (0)
- P.065 Precore and core promoter mutations or serum HBV DNA levels do not allow to distinguish true inactive HBsAg carriers from HBeAg negative chronic hepatitis B with fluctuating ALT (2006) (0)
- A Microrna-Based Diagnostic Tool to Predict Advanced Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B and C (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Patrick Marcellin?
Patrick Marcellin is affiliated with the following schools: